The complexity of p53 modulation: Emerging patterns from divergent signals

Genes and Development

Volumn 12, Issue 19, 1998, Pages 2973-2983

  Giaccia, Amato J ^a   Kastan, Michael B ^b  

^a STANFORD UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL CELL; GENE DELETION; GENE MUTATION; GROWTH INHIBITION; MALIGNANT TRANSFORMATION; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

ANIMALIA;

EID: 0032192140     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.12.19.2973     Document Type: Review

References (114)

1. Abramova, N.A., J. Russell, M. Botchan, and R. Li. 1997. Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner. Proc. Natl. Acad. Sci. 94: 7186-7191.
2. An, W.G., M. Kanekal, M.C. Simon, E. Maltepe, M.V. Blagosklonny, and L.M. Neckers. 1998. Stabilization of wild-type p53 by hypoxia-inducible factor 1a. Nature 392: 405-408.
3. Antoniades, H.N., T. Galanopoulos, J. Neville-Golden, C.P. Kirtsy, and S.E. Lynch. 1994. p53 expression during normal tissue regeneration in reponse to acute cutaneous injury in swine. J. Clin. Invest. 93: 2206-2214.
4. Avantaggiati, M.L., V. Ogryzko, K. Gardner, A. Giordano, A.S. Levine, and K. Kelly. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175-1184.
5. Banasiak, K.J. and G.G. Haddad. 1998. Hypoxia-induced apoptosis:effect of hypoxia severity and role of p53 in neuronal cell death. Brain Res. 797: 295-304.
6. Banin, S., L. Moyal, R. Khostravi, S.-Y. Shieh, Y. Taya, C.W. Anderson, L. Chessa, N.I. Smorodinsky, C. Prives, Y. Shiloh, and Y. Ziv. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (in press).
7. Baudier, J., C. Delphin, D. Grunwald, S. Khochbin, and J.J. Lawrence. 1992. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc. Natl. Acad. Sci. 89: 11627-11631.
8. Bischoff, J.R., P.N. Friedman, D.R. Marshak, C. Prives, and D. Beach. 1990. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl. Acad. Sci. 87: 4766-4770.
9. Calmels, S., P. Hainaut, and H. Ohshmia. 1997. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res. 57: 3365-3369.
10. Canman, C.E., A.C. Wolff, C.Y. Chen, A.J.J. Fornace, and M.B. Kastan. 1994. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res. 54: 5054-5058.
11. Canman, C.E., D.S. Lim, K.A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M.B. Kastan, and D.D. Siliciano. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (in press).
12. Chernov, M.V., C.V. Ramana, V.V. Adler, and G.R. Stark. 1998. Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proc. Natl. Acad. Sci. 95: 2284-2289.
13. Cho, Y., S. Gorina, P.D. Jeffrey, and N.P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
14. Debbas, M. and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & Dev. 7: 546-554.
15. Delmolino, L., H. Band, and V. Band. 1993. Expression and stability of p53 protein in human mammary epithelial cells. Carcinogenesis 14: 827-832.
16. Delphin, C., P. Cahen, J.J. Lawrence, and J. Baudier. 1994. Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. Eur. J. Biochem. 223: 683-692.
17. de Stanchina, E., M.E. McCurrach, F. Zindy, S.-Y. Shieh, G. Ferbeyte, A.V. Samulsen, C. Prives, M.F. Roussel, C.J. Sherr, and S.W. Lowe. 1998. E1A signaling to p53 involves the p19ARF tumor suppressor. Genes & Dev. 12: 2434-2442.
18. Dumaz, N., A. Duthu, J.C. Ehrhart, C. Drougard, E. Appella, C.W. Anderson, P. May, A. Sarasin, and L. Daya-Grosjean. 1997. Prolonged p53 protein accumulation in trichothiodystrophy fibroblasts dependent on unrepaired pyrimidine domers on the transcribed strands of cellular genes. Mol. Carcinog. 20: 340-347.
19. Dutta, A., J.M. Ruppert, J.C. Aster, and E. Winchester. 1993. Inhibition of DNA replication factor RPA by p53. Nature 365: 79-82.
20. Eckner, R., M.E. Ewen, D. Newsome, M. Gerdes, J.A. DeCaprio, J.B. Lawrence, and D.M. Livingston. 1994. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes & Dev. 8: 869-884.
21. Eckner, R., J.W. Ludlow, N.L. Lill, E. Oldread, Z. Arany, N. Modjtahedi, J.A. DeCaprio, D.M. Livingston, and J.A. Morgan. 1996. Association of p300 and CBP with simian virus 40 large T antigen. Mol. Cell. Biol. 16: 3454-3464.
22. Fu, L. and S. Benchimol. 1997. Participation of the human p53 3′ UTR translational repression and activation following gamma-irradiation. EMBO J. 16: 4117-4125.
23. Garkavtsev, I., I.A. Grigorian, V.S. Ossovskaya, M.V. Chernov, and A.V. Gudkov. 1998. The candidate tumor suppressor p33ING1 cooperates with p53 in cell growth control. Nature 391: 295-298.
24. Girinsky, T., C. Koumenis, T.G. Graeber, D.M. Peehl, and A.J. Giaccia. 1995. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res. 55: 3726-3731.
25. Goldman, S.C., C.Y. Chen, T.J. Lansing, T.M. Gilmer, and M.B. Kastan. 1996. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol. 148: 1381-1385.
26. Gottleib, T.M. and M. Oren. 1995. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287: 77-102.
27. Graeber, T.G., J.F. Peterson, M. Tsai, A.J. Fornace, Jr., and A.J. Giaccia. 1994. Hypoxia induces the accumulation of p53 protein, but the activation of a G1-phase checkpoint by low oxygen conditions is independent of p53 status. Mol. Cell Biol. 14: 6264-6277.
28. Graeber, T.G., C. Osmanian, T. Jacks, D.E. Housman, C.J. Koch, S.W. Lowe, and A.J. Giaccia. 1996. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-91.
29. Green, S.L. and A.J. Giaccia. 1998. Tumor hypoxia and the cell cycle: Implications for malignant progression and response to therapy. Cancer J. Sci. Am. 4: 218-223.
30. Gu, W. and R.G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
31. Gu, W., X.-L. Shi, and R.G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387: 819-822.
32. Hainaut, P. and J. Milner. 1993a. A structural role for metal ions in the "wild-type" conformation of the tumor suppresor protein p53. Cancer Res. 53: 1739-1742.
33. _. 1993b. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53: 4469-4473.
34. Hall, S.R., L.E. Campbell, and D.W. Meek. 1996. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional represssion but not transactivation. Nucleic Acids Res. 24: 1119-1126.
35. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
36. Heacock, C.S. and R.M. Sutherland. 1986. Induction characteristics of oxygen regulated proteins. Int. J. Radiat. Oncol. Biol. Phys. 12: 1287-1290.
37. Hermeking, H. and D. Eick. 1994. Mediation of c-myc induced apoptosis by p53. Science 265: 2091-2093.
38. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27.
39. Huang, L.C., K.C. Clarkin, and G.M. Wahl. 1996. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1-arrest. Proc. Natl. Acad. Sci. 93: 4827-4832.
40. Hupp, T.R. and D.P. Lane. 1994. Regulation of the crytic sequence-specific DNA binding function of p53 by protein kinases. Cold Spring Harb. Symp. Quant. Biol. 59: 195-206.
41. Hupp, T.R., D.W. Meek, C.A. Midgley, and D.P. Lane. 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21: 3167-3174.
42. Hupp, T.R., A. Sparks, and D.P. Lane. 1995. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83: 237-245.
43. Jayaraman, L. and C. Prives. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the C-terminus. Cell 81: 1021-1029.
44. Jayaraman, L., K.G. Murthy, C. Zhu, T. Curran, S. Xanthoudakis, and C. Prives. 1997. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes & Dev. 11: 558-570.
45. Jayaraman, L., N.C. Moorthy, K.G. Murthy, J.L. Manley, M. Bustin, and C. Prives. 1998. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes & Dev. 12:462-472.
46. Kamijo, T., J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. 95: 8292-8297.
47. Kapoor, M. and G. Lozano. 1998. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci. 95:2834-2837.
48. Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig. 1991. Participation of p53 in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
49. Kastan, M.B., Q. Zhan, W. El-Diery, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein, and A.J. Fornace. 1992. A mammalian cell-cycle checkpoint pathway utilizing p53 and gadd45 is detective in Ataxia-Telangiectasia. Cell 71: 587-597.
50. Khanna, K.K. and M.F. Lavin. 1993. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia telangiectasia cells. Oncogene 8: 3307-3312.
51. Kim, C.Y., M.H. Tsai, C. Osmanian, T.G. Graeber, J.E. Lee, R.G. Giffard, J.A. DiPaolo, D.M. Peehl, and A.J. Giaccia. 1997. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res. 57: 4200-4204.
52. Knippschild, U., D.M. Milne, L.E. Campbell, A.J. DeMaggio, E. Christenson, M.F. Hoekstra, and D.W. Meek. 1997. p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase I and enhances the level of casein kinase I delta in response to topoisomerase-directed drugs. Oncogene 15: 1727-1736.
53. Ko, L.J. and C. Prives. 1996. p53: Puzzle and paradigm. Genes & Dev. 10: 1054-1072.
54. Ko, L.J., S.Y. Shieh, X. Chen, L. Jayaraman, K. Tamai, Y. Taya, C. Prives, and Z.Q. Pan. 1997. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol. Cell. Biol. 17: 7220-7229.
55. Kubbutat, M.H., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
56. Lee, S., B. Elenbass, A. Levine, and J. Griffith. 1995. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020.
57. Lees-Miller, S.P., Y.-R. Chen, and C.W. Anderson. 1990. Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40T antigen, mouse p53, and the human Ku autoantigen. Mol. Cell. Biol.10: 6472-6481.
58. Levine, A.J. 1997. p53, the cellular gatekeper for growth and division. Cell 88: 323-331.
59. Lill, N.L., S.R. Grossman, D. Ginsberg, J. DeCaprio, and D.M. Livingston. 1997a. Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-827.
60. Lill, N.L., M.J. Tevethia, R. Eckner, D.M. Livingston, and N. Modjtahedi. 1997b. p300 family members associate with the carboxyl terminus of sivian virus 40 large tumor antigen. J. Virol. 71: 129-137.
61. Linke, S.P., K.C. Clarkin, A. DiLeonardo, A. Tsou, and G.M. Wahl. 1996. A reversible, p53 dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes & Dev. 10: 934-947.
62. Ljungman, M. and F. Zhang. 1996. Blockage of RNA polymerase as a possible trigger for UV light-induced apoptosis. Oncogene 13: 823-831.
63. Lowe, S.W. and H.E. Ruley. 1993. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes & Dev. 7: 535-545.
64. Lu, H. and A.J. Levine. 1995. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. 92: 5154-5158.
65. Lu, H., R.P. Fisher, P. Bailey, and A.J. Levine. 1997. The CDK-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhances its sequence-specific DNA binding activity in vitro. Mol. Cell. Biol. 17: 5923-5934.
66. Lu, H., Y. Taya, M. Ikeda, and A.J. Levine. 1998. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 at serine-389. Proc. Natl. Acad. Sci. 95: 6399-6402.
67. Maki, G.G. and P.M. Howley. 1997. Ubiquitination of p53 and p21 is differentially affected by ionizing radiation and UV radiation. Mol. Cell. Biol. 17: 355-363.
68. Maki, G.G., J.M. Huibregtse, and P.M. Howley. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56: 2649-2654.
69. Maltzman, W. and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689-1694.
70. Mayo, L.D., J.J. Turchi, and S.J. Berberich. 1997. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction wih p53. Cancer Res. 57: 5013-5016.
71. McCormick, W. and S. Penman. 1969. Regulation of protein synthesis in HeLa cells: Translation at elevated temperatures. J. Mol. Biol. 39:315-333.
72. Midgley, C.A. and D.P. Lane. 1997. p53 protein stability in tumor cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189.
73. Milne, D.M., R.H. Palmer, D.G. Campbell, and D.W. Meek. 1992. Phosphorylation of the p53 tumor-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene 7: 1361-1369.
74. Moll, U.M., G. Riou, and A.J. Levine. 1992. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc. Natl. Acad. Sci. 89: 7262-7266.
75. Moll, U.M., M. LaQuaglia, J. Benard, and G. Riou. 1995. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. 92:4407-4411.
76. Momand, J., G.P. Zambetti, D.C. Olson, D.L. Geoge, and A.J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivaton. Cell 69: 1237-1245.
77. Morgan, S.E. and M.B. Kastan. 1997. p53 and ATM: Cell cycle, cell death and cancer. Adv. Cancer Res. 71: 1-25.
78. Mosner, J., T. Mummenbrauer, C. Bauer, G. Sczakiel, F. Grosse, and W. Deppert. 1995. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14: 4442-4449.
79. Mullei-Tiemann, B.F., T.D. Halazonetis, and J.J. Elting. 1998. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl. Acad. Sci. 95: 6079-6084.
80. Nelson, W.G. and M. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14: 1815-1823.
81. Nigro, J.M., K.D. Aldape, S.M. Hess, and T.D. Tlsty. 1997. Cellular adhesion regulates p53 protein levels in primary human keatinocytes. Cancer Res. 57: 3635-3639.
82. Oliner, J.D., J.A. Pietenpol, S. Thiagalingam, J. Gyuris, K.W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362: 857-860.
83. Pearson, G.D. and G.F. Merrill. 1998. Deletion of the Saccharomyces cerevisiae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression. J. Biol. Chem. 273: 5431-5434.
84. Pettersen, E.O., N.O. Juul, and O.W. Ronning. 1986. Regulation of protein metabolism of human cells during and after acute hypoxia. Cancer Res. 46: 4346-4351.
85. Polyak, K., Y. Xia, J.L. Zweier, K.W. Kinzler, and B. Vogelstein. 1997. A model for p53-induced apoptosis. Nature 389: 300-305.
86. Pomerantz, J., N. Schreiber-Agus, N.J. Liegeois, A. Silverman, L. Alland, L. Chin, T. Potes, K. Chen, I. Orlow, H.W. Lee, C. Cordon-Cardo, and R.A. DePinho. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
87. Price, B.D. and S.K. Calderwood. 1993. Increased sequence-specific p53-DNA binding activity after DNA damage is attenuated by phorbol esters. Oncogene 8: 3055-3062.
88. Price, B.D., L. Hughes-Davies, and S.J. Park. 1995. Cdk2 kinase phosphorylates serine 315 of human p53 in vitro. Oncogene 11: 73-80.
89. Roth, J., M. Dobbelstein, D.A. Freedman, T. Shenk, and A.J. Levine. 1998. Nucleo-cytoplasmic shutling of the mdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554-564.
90. Sakaguchi, K., H. Sakamoto, M.S. Lewis, C.W. Anderson, J.W. Erickson, E. Apella, and D. Xie. 1997. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36: 10117-10124.
91. Sakaguchi, K., J.E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C.W. Anderson, and E. Appella. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes & Dev. 12: 2831-2841.
92. Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine, and P.M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
93. Schwartz, D., N. Goldfinger, and V. Rotter. 1993. Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene 8: 1487-1494.
94. Scolnick, D.M., N.H. Chehab, E.S. Stavridi, M.C. Lien, L. Caruso, E. Moran, S.L. Berger, and T.D. Halazonetis. 1997. CREB-binding protein and p300/CBP-assocaited factor are transciptional coactivators of the p53 tumor suppressor protein. Cancer Res. 57: 3693-3696.
95. Selivanova, G., V. Iotsova, I. Okan, M. Pritsche, M. Storm, B. Groner, R.C. Crafstorm, and K.G. Wilman. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from p53 C-terminal domain. Nat. Med. 3: 632-638.
96. Serrano, M., A.W. Lin, M.E. McCurrach, D. Beach, and S.W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
97. Sherr, C.J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes & Dev. (this issue).
98. Shieh, S.-Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
99. Siliciano, J.D., C.E. Canman, Y. Taya, K. Sakaguchi, E. Appella, and M.B. Kastan. 1997. DNA damage induces phosphorylation of the amino terminus of p53. Genes & Dev. 11: 3471-3481.
100. Steegenga, W.T., T. van Laar, N. Riteco, A. Manarino, A. Shvarts, A.J. van der Eb, and A.G. Jochemsem. 1996. Adenovirus E1A proteins inhibit activation of transcription by p53. Mol. Cell. Biol. 16: 2101-2109.
101. Stoler, D.L., G.R. Anderson, C.A. Russo, A.M. Spina, and T.A. Beerman. 1992. Anoxia-inducible endonuclease activity as a potential basis of the genomic instability of cancer cells. Cancer Res. 52: 4372-4378.
102. Takenaka, I., F. Morin, B.R. Seizinger, and N. Kley. 1995. Regulation of the sequence-specific DNA binding function of p53 by potein kinase C and protein phosphatases. J. Biol. Chem. 270: 5405-5411.
103. Thut, C. J., J.-L. Chen, R. Klemm, and R. Tjian. 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267: 100-104.
104. Thut, C.J., J.A. Goodrich, and R. Tjian. 1997. Repression of p53-mediated transription by MDM2: A dual mechanism. Genes & Dev. 11: 1974-1986.
105. Venot, C., M. Maratrat, C. Dureuil, E. Conseiller, L. Bracco, and L. Debussche. 1998. The requirement for the p53 prolinerich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17: 4668-4679.
106. Verhaegh, G.W., M.J. Richard, and P. Hainaut. 1997. Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper. Mol. Cell. Biol. 17: 5699-5706.
107. wat-1/cip1. Genes & Dev. 8: 2817-2830.
108. Walker, K.K. and A.J. Levine. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. 93: 15335-15340.
109. Waterman, M.J.F., E.S. Stavridi, J.L.F. Waterman, and T.D. Halazonetis. 1998. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genet. 19: 175-178.
110. Weinberg, W.C., C.G. Azzoli, K. Chapman, A.J. Levine, and S.H. Yuspa. 1995. p53-mediated transcriptional activity increases in differentiating epidermal kearatinocytes in association with decreased p53 protein. Oncogene 10: 2271-2279.
111. Werness, B.A., A.J. Levine, and P.M. Howley. 1990. Association of human papillomavirus types 16 and 18 proteins with p53. Science 248: 76-79.
112. Woo, R.A., K.G. McLure, S.P. Lees-Miller, D.E. Rancourt, and P.W.K. Lee. 1998. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394: 700-704.
113. Zhang, Y., Y. Xiong, and W.G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
114. Zindy, F., C.M. Eischen, d. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & Dev. 12: 2424-2433.